𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

✍ Scribed by Socrates E. Papapoulos; Sara A. Quandt; Uri A. Liberman; Marc C. Hochberg; Desmond E. Thompson

Publisher
Springer-Verlag
Year
2004
Tongue
English
Weight
233 KB
Volume
16
Category
Article
ISSN
0937-941X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Arzoxifene for prevention of fractures a
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
✍ Steven R Cummings; Michael McClung; Jean-Yves Reginster; David Cox; Bruce Mitlak πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 97 KB

## Abstract Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. In a randomized, blinded trial, women aged 60 to 85 years with osteoporosis, defined

Efficacy of continued alendronate for fr
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial
✍ Ann V Schwartz; Douglas C Bauer; Steven R Cummings; Jane A Cauley; Kristine E En πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 102 KB

## Abstract In the Fracture Intervention Trial (FIT) Long Term Extension (FLEX) Trial, 10 years of alendronate (ALN) did not significantly reduce the risk of nonvertebral fractures (NVFs) compared with 5 years of ALN. Continuing ALN reduced the risk of clinical but not morphometric vertebral fractu